Keros Therapeutics, Inc. (KROS)
NASDAQ:KROS
Want to see KROS full AI Analyst Report?
Total Valuation
Keros Therapeutics has a market cap or net worth of $217.31M. The enterprise value is $86.15M.
Market Cap$217.31M
Enterprise Value$86.15M
Share Statistics
Keros Therapeutics has 19,791,838 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding19,791,838
Owned by Insiders50.90%
Owned by Institutions3.02%
Financial Efficiency
Keros Therapeutics’s return on equity (ROE) is 0.29 and return on invested capital (ROIC) is 20.90%.
Return on Equity (ROE)0.29
Return on Assets (ROA)0.26
Return on Invested Capital (ROIC)20.90%
Return on Capital Employed (ROCE)0.22
Revenue Per Employee1.50M
Profits Per Employee533.83K
Employee Count163
Asset Turnover0.72
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Keros Therapeutics is ―. Keros Therapeutics’s PEG ratio is -0.06.
PE Ratio―
PS Ratio3.11
PB Ratio2.50
Price to Fair Value2.50
Price to FCF7.15
Price to Operating Cash Flow-7.15
PEG Ratio-0.06
Income Statement
In the last 12 months, Keros Therapeutics had revenue of 244.06M and earned 87.01M in profits. Earnings per share was 2.34.
Revenue244.06M
Gross Profit242.55M
Operating Income70.62M
Pretax Income91.90M
Net Income87.01M
EBITDA72.13M
Earnings Per Share (EPS)2.34
Cash Flow
In the last 12 months, operating cash flow was -57.20M and capital expenditures -1.06M, giving a free cash flow of -58.25M billion.
Operating Cash Flow-57.20M
Free Cash Flow-58.25M
Free Cash Flow per Share-2.94
Dividends & Yields
Keros Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.96
52-Week Price Change-21.79%
50-Day Moving Average11.36
200-Day Moving Average15.37
Relative Strength Index (RSI)46.01
Average Volume (3m)328.87K
Important Dates
Keros Therapeutics upcoming earnings date is Aug 12, 2026, Before Open (Confirmed).
Last Earnings DateMay 14, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Keros Therapeutics as a current ratio of 15.45, with Debt / Equity ratio of 5.71%
Current Ratio15.45
Quick Ratio15.45
Debt to Market Cap<0.01
Net Debt to EBITDA-3.75
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Keros Therapeutics has paid 4.88M in taxes.
Income Tax4.88M
Effective Tax Rate0.05
Enterprise Valuation
Keros Therapeutics EV to EBITDA ratio is 6.76, with an EV/FCF ratio of 4.60.
EV to Sales2.00
EV to EBITDA6.76
EV to Free Cash Flow4.60
EV to Operating Cash Flow4.53
Balance Sheet
Keros Therapeutics has $281.50M in cash and marketable securities with $16.31M in debt, giving a net cash position of $265.19M billion.
Cash & Marketable Securities$281.50M
Total Debt$16.31M
Net Cash$265.19M
Net Cash Per Share$13.40
Tangible Book Value Per Share$8.14
Margins
Gross margin is 96.48%, with operating margin of 28.94%, and net profit margin of 35.65%.
Gross Margin96.48%
Operating Margin28.94%
Pretax Margin37.65%
Net Profit Margin35.65%
EBITDA Margin29.55%
EBIT Margin28.94%
Analyst Forecast
The average price target for Keros Therapeutics is $21.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$21.20
Price Target Upside81.66% Upside
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast-84.55%
EPS Growth Forecast-1998.74%